Intravitreal ranibizumab for the treatment of cystoid macular edema in Irvine-Gass syndrome.

Abstract

PURPOSE:

To evaluate the functional and anatomical outcome after intravitreal ranibizumab injection in 2 patients with cystoid macular edema (CME) related to Irvine-Gass syndrome.

METHODS:

Two patients with pseudophakic CME refractory to current standard topical treatment were enrolled in this study. Intravitreal (0.5 mg/0.05 mL) ranibizumab injection was performed. Baseline visits included best-corrected visual acuity (BCVA), a fundus examination, optical coherence tomography (OCT), and fundus fluorescein angiography (FA). The main outcome measures were changes in visual acuity, retinal thickness on OCT, and complications related to treatment.

RESULTS:

FA and OCT confirmed the diagnosis of pseudophakic CME in both cases. The initial BCVA was 5/100 in the first case. After 1 injection of intravitreal ranibizumab, retinal edema totally regressed and BCVA improved to 6/10. The central macular thickness (CMT) measured with OCT was 379 μm at baseline and decreased to 227 μm at the 16-month visit. The initial BCVA was 5/10 in the second case. It improved to 8/10 after 2 ranibizumab injections and remained unchanged at the 21-month visit. The CMT measured with OCT was 419 μm at baseline and decreased to 243 μm at the final follow-up. There were no ocular or systemic complications related to the intravitreal injections.

CONCLUSION:

Intravitreal ranibizumab appeared to be an effective treatment of macular edema related to Irvine-Gass syndrome. Prospective controlled studies are warranted to compare the long-term safety and efficacy between intravitreal ranibizumab and other treatment options in cases of Irvine-Gass syndrome.

• Authors: Sibel Demirel, Figen Batioğlu, Emin Özmert
• Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics (J Ocul Pharmacol Ther) Vol. 28 Issue 6 Pg. 636-9 (Dec 2012) ISSN: 1557-7732 [Electronic] United States
• PMID: 22731243 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Aged
• Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
• Fluorescein Angiography
• Follow-Up Studies
• Humans
• Intravitreal Injections
• Macular Edema (drug therapy, pathology)
• Male
• Ranibizumab
• Retina (drug effects, pathology)
• Time Factors
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (drug effects)